Trimetazidine and Other Metabolic Modifiers

Jul 22, 2020

Overview : Although cardiovascular mortality has declined progressively in developed countries, ischaemic heart disease (IHD) and chronic stable angina cause a worse prognosis and poor quality of life and can dramatically increase healthcare costs.1–4 Traditionally, chronic stable angina has been interpreted as reversible... more

Role Of Anti-Inflammatory Interventions In Coronary Artery Disease: Understanding CANTOS

Mar 02, 2020

Overview :   Coronary artery disease (CAD) is the leading cause of death in most countries. Compelling evidence from epidemiological, genetic and clinical studies as well as experiments in animal models has unquestionably established that elevated concentrations of cholesterol (mainly transported by... more

Management Of Severe Dyslipidaemia: Role Of PCSK9 Inhibitors

Dec 12, 2019

Overview :   Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is... more

Key Recent Advances In Atherosclerosis Treatment With Modern Lipid-Lowering Drugs: The New Frontier With PCSK9 Inhibitors

Jan 04, 2019

Overview : Hypercholesterolemia has been known for several years to be a major risk factor in the development of atherosclerosis and consecutively cardiovascular disease. This epidemiological concept has been widely confirmed using different strategies that have reduced low-density lipoprotein (LDL) levels and... more

Cardiovascular Risk Management Targeting Inflammation In Addition To Lipid-Lowering Therapy

Dec 13, 2017

Overview : Myocardial infarction is often caused by the rupture of unstable plaque in atherosclerosis with mild-to-moderate stenosis. Research has revealed that local tissue inflammation is closely involved in the rupture of atherosclerotic plaque.1 Stabilization of atherosclerotic plaque by strictly managing the... more

Inflammation Revisited: Atherosclerosis in the Post-CANTOS Era

Oct 04, 2017

Overview : The notion that atherosclerosis carries features of an inflammatory disease has existed for quite some time. As early as 1856, Rudolf Virchow in his Textbook on Pathology mentioned the term “coronaritis”. Almost 150 years later, following the elucidation of major... more

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events–Reduction of Cholesterol to Key European Targets Trial.

Aug 17, 2015

Overview : The debate over the cholesterol hypothesis and statins has raged for decades. The early period following the onset of acute coronary syndrome represents a critical stage of coronary heart disease, with a high risk of recurrent events and deaths. The... more

A LONG-AWAITED LDL LOWERING STUDY USING COMBINATION THERAPY IS PRESENTED BY RESEARCHERS

Dec 03, 2014

Overview : STUDY DESIGN A total of 18,144 patients were randomized in 1:1 blinded fashion either to ezetimibe / simvastatin (n=9,067) or to simvastatin alone (n=9,077). The inclusion criteria were (a) hospitalization for ST-elevation myocardial infarction (MI), non ST-elevation myocardial infarction or... more

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study

Jun 18, 2012

Overview : The present study sought to assess whether there is a causal relationship between raising HDL and the risk for myocardial infarction (MI). Using a mendelian randomization, the authors found that in patients with genetically higher HDL the risk of MI... more

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy

Jun 18, 2012

Overview : In the present study the authors aimed to replicate the earlier observation from the Framingham Offspring Study that changes in HDL-C associated with lipid modification therapy are associated with a lower risk of cardiovascular events independent of changes in LDL-C... more

Page: